Aus­tralian spin­out eyes the clin­ic with a pro­phy­lac­tic nasal spray for Covid-19

Whether pa­tients are im­muno­com­pro­mised or just don’t like nee­dles, one fledg­ling Aus­tralian biotech says it has an al­ter­na­tive to Covid-19 vac­cines that doesn’t in­volve a jab in the arm — and on Tues­day, it pulled in a fresh round of fund­ing to take it in­to the clin­ic.

ENA Res­pi­ra­to­ry, which spun out of ENA Ther­a­peu­tics last year, has pulled in near­ly $24.7 mil­lion (AU $30 mil­lion) to ad­vance its nasal spray for res­pi­ra­to­ry vi­ral in­fec­tions, the com­pa­ny said Tues­day.

The fund­ing, trig­gered by mile­stones, was led by Aus­tralian in­vestors Bran­don Cap­i­tal Part­ners and Min­deroo Foun­da­tion, with Uniseed chim­ing in.

ENA’s lead can­di­date, IN­NA-051, is a small mol­e­cule that tar­gets the TLR2/6 re­cep­tors on air­way ep­ithe­lial cells to boost the body’s nat­ur­al im­mune re­sponse to virus­es. It’s set to en­ter the clin­ic “in the com­ing weeks,” ac­cord­ing to the ENA.

Christophe De­mai­son

“Along­side vac­cines, there is a need for com­ple­men­tary ap­proach­es to help pro­tect the most vul­ner­a­ble peo­ple and al­so pro­vide pro­tec­tion against emerg­ing vari­ants,” co-founder and CEO Christophe De­mai­son said in a state­ment.

He sees the spray as es­pe­cial­ly use­ful for peo­ple who are el­der­ly or im­muno­com­pro­mised, and can’t mount a suf­fi­cient re­sponse to cur­rent­ly avail­able vac­cines. It would be self-ad­min­is­tered once or twice a week, ei­ther be­fore or short­ly af­ter ex­po­sure. And be­cause it’s not virus-spe­cif­ic, ENA be­lieves IN­NA-051 could ward off oth­er ill­ness­es like the flu and com­mon cold, as well as emerg­ing Covid-19 vari­ants.

Back in De­cem­ber, ENA pub­lished re­sults in EBio­Med­i­cine show­ing that a group of fer­rets treat­ed with IN­NA-051 in a chal­lenge study saw re­duced vi­ral repli­ca­tion of up to 96%.

“If hu­mans re­spond in a sim­i­lar way, the ben­e­fits of treat­ment are two-fold,” De­mai­son said at the time. “In­di­vid­u­als ex­posed to the virus would most like­ly rapid­ly elim­i­nate it, with the treat­ment en­sur­ing that the dis­ease does not progress be­yond mild symp­toms. This is par­tic­u­lar­ly rel­e­vant to vul­ner­a­ble mem­bers of the com­mu­ni­ty. In ad­di­tion, the ra­pid­i­ty of this re­sponse means that the in­fect­ed in­di­vid­u­als are un­like­ly to pass it on, mean­ing a swift halt to com­mu­ni­ty trans­mis­sion.”

In ad­di­tion to the fund­ing, ENA is tap­ping Glax­o­SmithK­line vet Ruth Tal-Singer to its board of di­rec­tors. While she’s cur­rent­ly pres­i­dent and CSO of the non­prof­it COPD Foun­da­tion, Tal-Singer once held a va­ri­ety of se­nior roles at the phar­ma, in­clud­ing VP of med­ical in­no­va­tion and VP of res­pi­ra­to­ry R&D.

Nasal sprays have gained in­creas­ing in­ter­est as an al­ter­na­tive for those who can’t ben­e­fit from vac­cines in the last year. Back in No­vem­ber, gene ther­a­py pi­o­neer James Wil­son and his col­leagues at the Uni­ver­si­ty of Penn­syl­va­nia inked a pact with Re­gen­eron to see if they could com­bine the biotech’s Covid-19 an­ti­body cock­tail with a nasal spray-based AAV de­liv­ery plat­form. And back in March, GV led a $47 mil­lion round to fund Ley­den Labs’ mis­sion to de­vel­op a nasal spray that could pro­tect peo­ple from a whole range of virus­es for a few days.

At the In­flec­tion Point for the Next Gen­er­a­tion of Can­cer Im­munother­a­py

While oncology researchers have long pursued the potential of cellular immunotherapies for the treatment of cancer, it was unclear whether these therapies would ever reach patients due to the complexity of manufacturing and costs of development. Fortunately, the recent successful development and regulatory approval of chimeric antigen receptor-engineered T (CAR-T) cells have demonstrated the significant benefit of these therapies to patients.

All about Omi­cron; We need more Covid an­tivi­rals; GSK snags Pfiz­er’s vac­cine ex­ec; Janet Wood­cock’s fu­ture at FDA; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

The slate of products we’re offering here at Endpoints is continuing to grow, and it’s not just limited to editorial. If you haven’t, do visit your reader profile to see if there are any other weekly newsletters you’re interested in — as each comes with its own exclusive content. And don’t miss the publisher’s note from Arsalan Arif on Endpoints Studio, our latest avenue for advertising on Endpoints.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Lisa Deschamps, AviadoBio CEO

Ex-No­var­tis busi­ness head hops over to a gene ther­a­py start­up — and she's reeled in $80M for a dash to the clin­ic

Neurologist and King’s College London professor Christopher Shaw has been researching neurodegenerative diseases like ALS and collaborating with drugmakers for the last 25 years in the hopes of pushing new therapies forward. But unfortunately, none of those efforts have come anywhere close to fruition.

“So, you know, after 20 years in the game, I said, ‘Let’s try and do it ourselves,’” he told Endpoints News. 

Merck's new antiviral molnupiravir (Quality Stock Arts / Shutterstock)

As Omi­cron spread looms, oral an­tivi­rals ap­pear to be one of the best de­fens­es — now we just need more

After South African scientists reported a new Covid-19 variant — dubbed Omicron by the WHO — scientists became concerned about how effective vaccines and monoclonal antibodies might be against it, which has more than 30 mutations in the spike protein.

“I think it is super worrisome,” Dartmouth professor and Adagio co-founder and CEO Tillman Gerngross told Endpoints News this weekend. Moderna CEO Stéphane Bancel echoed similar concerns, telling the Financial Times that experts warned him, “This is not going to be good.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Radek Spisek, Sotio CEO (Cellestia)

A qui­et Czech biotech bags $315M to dri­ve its blos­som­ing can­cer pipeline through the clin­ic

In the rather insular world of biotech, most innovation inevitably comes from a cluster of R&D hubs — Cambridge, San Francisco, etc. But sometimes success stories sprout from rocky soil, which is most certainly the case with Prague-based Sotio Biotech and its suddenly jam-packed pipeline of cancer drugs.

After years in quiet development, Sotio now has $315 million in new funds to play with from parent company PPF Group, an investment group founded in the Czech Republic, as the biotech looks to advance its growing pipeline through early- and mid-stage trials.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

In­cor­po­rat­ing Ex­ter­nal Da­ta in­to Clin­i­cal Tri­als: Com­par­ing Dig­i­tal Twins to Ex­ter­nal Con­trol Arms

Most drug development professionals are familiar with the nerve-racking wait for the read-out of a large trial. If it’s negative, is the investigational therapy ineffective? Or could the failure result from an unforeseen flaw in the design or execution of the protocol, rather than a lack of efficacy? The team could spend weeks analyzing data, but a definitive answer may be elusive due to insufficient power for such analyses in the already completed trial. These problems are only made worse if the trial had lower enrollment, or higher dropout than expected due to an unanticipated event like COVID-19. And if a trial is negative, the next one is likely to be larger and more costly — if it happens at all.

Ab­b­Vie tacks on a new warn­ing to Rin­voq la­bel as safe­ty frets crimp JAK class

The safety problems that continue to plague the JAK class as new data highlight some severe side effects are casting a large shadow over AbbVie’s Rinvoq.

As a result of a recent readout highlighting major adverse cardiac events (MACE), malignancy, mortality and thrombosis with Xeljanz a couple of months ago, AbbVie put out a notice late Friday afternoon that it is adding the new class risks to its label for their rival drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.

Biospec­i­men M&A: Dis­cov­ery ac­quires Al­bert Li's he­pa­to­cyte project; PhI­II tri­al on Bay­er's Nube­qa reached pri­ma­ry end­point

Discovery Life Sciences has acquired what claims to be the Maryland-based host of the world’s largest hepatocyte inventory, known as IVAL, to help researchers select more effective and safer drug candidates in the future.

The combined companies will now serve a wider range of drug research and development scientists, according to Albert Li, who founded IVAL in 2004 and is set to join the Discovery leadership team as the CSO of pharmacology and toxicology.

Pfiz­er, Am­gen and Janssen seek fur­ther clar­i­ty on FDA's new ben­e­fit-risk guid­ance

Three top biopharma companies are seeking more details from the FDA on how the agency conducts its benefit-risk assessments for new drugs and biologics.

While Pfizer, Amgen and Janssen praised the agency for further spelling out its thinking on the subject in a new draft guidance, including a discussion of patient experience data as part of the assessment, the companies said the FDA could’ve included more specifics in the 20-page draft document.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 124,600+ biopharma pros reading Endpoints daily — and it's free.